Hot St0ck in motion

[Bernard Knox]

Tip Top Equities Late-September Issue


Make no mistake: Our mission at Tip Top Equities is to
sift through the thousands of underperforming
companies out there to find the golden needle in the
haystack.  The micro-cap DIAMOND that can make
you a fortune.  More often than not, the stocks we
profile show a significant increase in stock price,
sometimes in days, not months or years.  We have come
across what we feel is one of those rare deals that the
public has not heard about yet.  Read on to find out
more.


Company: Ascentia Biomedical

Symbol: ASCE . PK

This company already gained 50% on Wednesday.  We
believe it is poised to go higher!

Current price around :                  $0.90
Short Term Target Price:                $1.90
12 month Target Price:                  $2.80

***About the Company***

First, do a search on Acentia Biomedical with your
favorite search engine.  This is going to give you more
detailed information than we are able to provide here.

You will find that:

Ascentia Biomedical Corporation's core business is the
development of promising pharmaceutical families that
have already undergone significant discovery,
exploration and testing. The company seeks to
strengthen its strategic and financial position by
identifying additional indications for these compounds.
Ascentia will search for additional products in order to
diversify. New products emerge from in-house research
focused on related compounds as well as through
outright purchase or licensing. Products are also
sourced throughout the world through the extensive
network of the company's research team, particularly in
the People's Republic of China. Additionally, promising
products will be identified through contractual
relationships.

Ascentia will focus on therapies for two primary
disease categories:

+Immune-based diseases such as asthma and arthritis
+Cancer

***Big news out for ASCE***

Ascentia Biomedical Receives $1 Million Funding
Commitment to Support Continued Research and
Organizational Growth

BELLEVUE, WA. September 14, 2005 Ascentia
Biomedical Corporation, a leading researcher and
developer of efficacious pharmaceuticals, compounds
and other products, announces it has received an initial
commitment for up to $1 million in funding for
continued research particularly in anti-cancer
compounds and for organizational growth.

The financing will come in the form of a series of
separate convertible notes through Winsted Holdings
Inc., Newport Beach, California, a highly respected
Business Development Company.

Dr. James Clagett, President & CEO of Ascentia
Biomedical said, “This round of funding underscores
the confidence and value Winsted has in our research
and our exceptional scientific advisory board. It is a
vote of confidence that further strengthens our efforts to
provide the most comprehensive and cost-effective
pharmaceutical research and development. This
expansion round should position Ascentia to serve our
customers with quality, innovative product solutions
and efficacious pharmaceuticals.”


The time to get in on this company is now.  Big News is
expected to move this company from "diamond in the
rough" to "stellar performer".


Watch this one trade all week!




Information within this email contains "forward looking
statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21B of the
Securities Exchange Act of 1934. Any statements that
express or involve discussions with respect to
predictions, goals,
expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance are not
statements of historical fact and may be "forward
looking statements."
Forward looking statements are based on expectations,
estimates and projections at the time the statements are
made that involve a number of risks and uncertainties
which could cause actual results or events to differ
materially from those presently anticipated.
Forward looking statements in this action may be
identified through the use of words such as: "projects",
"foresee", "expects", "estimates," "believes,"
"understands" "will," "part of: "anticipates," or that by
statements indicating certain actions "may," "could," or
"might" occur. All information provided within this
email pertaining to investing, stoc.ks, securities must be
understood as information provided and not investment
advice.
Emerging Equity Alert advises all readers and
subscribers to seek advice from a registered
professional securities representative before deciding to
trade in stoc.ks featured within this email. None of the
material within this report shall be construed as any
kind of investment advice. Please have in mind that the
interpretation of the writer of this newsletter about the
news published by the company does not represent the
company official statement and in fact may differ from
the real meaning of what the news release meant to say.
Look at the news release by yourself and judge by
yourself about the details in it.